JP2004528385A5 - - Google Patents

Download PDF

Info

Publication number
JP2004528385A5
JP2004528385A5 JP2002589442A JP2002589442A JP2004528385A5 JP 2004528385 A5 JP2004528385 A5 JP 2004528385A5 JP 2002589442 A JP2002589442 A JP 2002589442A JP 2002589442 A JP2002589442 A JP 2002589442A JP 2004528385 A5 JP2004528385 A5 JP 2004528385A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
compound
free
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002589442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528385A (ja
JP4150597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/005240 external-priority patent/WO2002092556A1/en
Publication of JP2004528385A publication Critical patent/JP2004528385A/ja
Publication of JP2004528385A5 publication Critical patent/JP2004528385A5/ja
Application granted granted Critical
Publication of JP4150597B2 publication Critical patent/JP4150597B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002589442A 2001-05-14 2002-05-13 スルホンアミド誘導体 Expired - Fee Related JP4150597B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29082701P 2001-05-14 2001-05-14
PCT/EP2002/005240 WO2002092556A1 (en) 2001-05-14 2002-05-13 Sulfonamide derivatives

Publications (3)

Publication Number Publication Date
JP2004528385A JP2004528385A (ja) 2004-09-16
JP2004528385A5 true JP2004528385A5 (enExample) 2005-12-22
JP4150597B2 JP4150597B2 (ja) 2008-09-17

Family

ID=23117717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589442A Expired - Fee Related JP4150597B2 (ja) 2001-05-14 2002-05-13 スルホンアミド誘導体

Country Status (13)

Country Link
US (1) US7109203B2 (enExample)
EP (1) EP1389183B1 (enExample)
JP (1) JP4150597B2 (enExample)
CN (1) CN1268610C (enExample)
AR (1) AR035891A1 (enExample)
AT (1) ATE459598T1 (enExample)
BR (1) BR0209386A (enExample)
CA (1) CA2443721A1 (enExample)
DE (1) DE60235536D1 (enExample)
ES (1) ES2340664T3 (enExample)
PE (1) PE20021158A1 (enExample)
PT (1) PT1389183E (enExample)
WO (1) WO2002092556A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
RU2447081C2 (ru) 2006-02-03 2012-04-10 Си Ви Терапьютикс, Инк. Способ получения агониста a2a-аденозинового рецептора и его полиморфов
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2662278C (en) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
EP2268612B1 (en) * 2008-03-24 2014-08-20 Novartis AG Arylsulfonamide-based matrix metalloprotease inhibitors
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ, インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ
EP2316820A1 (en) 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
ES2621085T3 (es) * 2013-06-14 2017-06-30 Dompé Farmaceutici S.P.A. Antagonistas del receptor de bradiquinina y composiciones farmacéuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE120047C (enExample) *
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
WO2001024786A1 (en) * 1999-05-13 2001-04-12 Shionogi & Co., Ltd. Preventive or therapeutic drugs for diabetes
GB9913079D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2004528385A5 (enExample)
JP3800220B2 (ja) 酢酸アニリド誘導体のα型又はβ型結晶
JP2005053931A5 (enExample)
JP2008511601A5 (enExample)
JP2006526031A5 (enExample)
JP2010526146A5 (enExample)
JP2006513268A5 (ja) アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体
JP2003532731A5 (enExample)
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2008505117A5 (enExample)
JP2004535466A5 (enExample)
CN1173959C (zh) 在2 -位携带具有磺酰胺结构或砜结构的取代基的8, 8a -二氢茚并 [1,2-d ]噻唑衍生物、它们的制备方法和它们作为药物的用途
JP2004533479A5 (enExample)
JP2005530811A5 (enExample)
JP2004131511A5 (enExample)
RU2005121908A (ru) Производные зн-хиназолин-4-она
JP2007515467A5 (enExample)
JP2002526522A5 (enExample)
JP2012511558A5 (enExample)
JP2005533760A5 (enExample)
JP2018502911A5 (enExample)
MX2007013606A (es) (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
JP2002538148A (ja) 多環2−アミノチアゾール系、その製造方法およびそれを含む医薬
JP2002538117A (ja) 肥満の予防または治療のための医薬の製造のための多環2−アミノチアゾール系の使用
JP2004502767A5 (enExample)